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HowSimilar Are theDisorders IncludedUnder the
Umbrella of Obsessive-Compulsive Disorder and
RelatedDisorders?
To the Editor In JAMA Psychiatry, Grant and colleagues1 dem-
onstrated the efficacy of N-acetylcysteine (NAC) in the
treatment of excoriation disorder (ED). The same group had
previously reported the benefits of NAC for adults with
trichotillomania (TTM).2 In both studies, NAC was used in
monotherapy in otherwise treatment-free patients. In the
DSM-5, ED and TTM were included under the umbrella of
obsessive-compulsive disorder (OCD) and related disorders
because of similarities regarding phenotypic expression
and common putative neurobiological underpinnings
between these disorders and OCD. When used for
treatment-resistant OCD, NAC was not more effective than
placebo as a selective serotonin reuptake inhibitor (SSRI)
augmentation strategy.3
In striking contrast withwhat we know about OCD, SSRIs
have not been proved to be superior to placebo in TTM
treatment.2 As for ED, the evidence regarding the efficacy of
SSRIs is still scarce.1 So far, there are noUSFood andDrugAd-
ministration–approved treatments for ED and TTM. The di-
vergent results of the trials testing either SSRIs orNAC for ED/
TTM and OCD suggest that treatments may not be used
interchangeably between OCD and related disorders. Despite
thepossiblemethodological issues related to thedesignof spe-
cific trials, do such heterogeneous results regarding treat-
ment response relate to heterogeneous neurobiology be-
tween OCD and related disorders?
Pathological grooming behaviors in animals are widely
used in the literature as a common animal model of ED/TTM
and OCD. However, findings derived from animal studies do
not always confirm the associationbetweengroomingbehav-
ior andOCD.For example, nodifferenceswereobserved in the
results of themarble-burying test of rats with different levels
of grooming behavior.4
In addition, results from genetic studies also suggest
that the neurobiology of pathological grooming may not be
necessarily related to OCD. It had been demonstrated that
Sapap3 knockout mice groomed themselves excessively.
However, using family-based association analyses, Bienv-
enu et al5 found that variation within the human equivalent
of the Sapap3 gene appeared associated with ED/TTM, but
not with OCD.
The conflicting results regarding the efficacy of NAC for
ED/TTM and OCD, in addition to the findings of translational
studies, suggest that the neural basis of repetitive behaviors
observed in patients with these disorders might not be the
same. So far, similarities between ED/TTM and OCD do not
seem to go beyond the characterization by repetitive behav-
iors and some degree of familial aggregation.
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In ReplyCosta and colleagues raise important issues regarding
howgroomingdisorders (GDs) shouldbeoptimally treatedand
classified.
N-acetylcysteine (NAC) showed superiority over placebo
asmonotherapy in excoriationdisorder,1 similar to findings in
trichotillomania. However, NAC’s findings in obsessive-
compulsive disorder (OCD) are mixed. Two clinical trials re-
ported significant benefits of NAC augmentation over pla-
cebo forOCD,2,3while a third studydidnot showbenefits over
placebo.4 As Costa and colleagues suggest, differential phar-
macological response across disorders is an important factor
when considering diagnostic classification. This is also com-
plicated by differences in study designs, as results may vary
whenusingNACasaugmentation toaselectiveserotonin reup-
take inhibitor rather than a primary intervention.
A common link between GD and OCD is an appealing no-
tion based on overt symptoms: these conditions are charac-
terized by repetitive acts that are difficult to suppress. There
is evidence for familial and comorbid overlap as well, but
whether this overlap is stronger than between GD and other
disorders (eg, alcoholismorattention-deficit/hyperactivitydis-
order) is less clear. Neuropsychological deficits in OCD span a
broader range of domains than those identified in GD. Even
without these differences, the neurobiological underpin-
nings may differ between disorders. Also, cognitive dysfunc-
tion is heterogeneous evenwithin a given disorder: while pa-
tient groups may manifest general cognitive deficits relative
tocontrol groups, theseproblemsmaynotalwayspersistwhen
assessed on an individual basis. The logical question then is
whether cognitive, imaging, or other markers could be used
to individualize treatment based on unique clinical features,
possibly transdiagnostically.
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We agreewith the caveats by Costa et al regarding animal
models of GD and OCD. In our experience, some animal
models of OCD are in fact measuring excessive grooming,
while other models of excessive grooming bear little face
validity with human disorders, such as animals who exces-
sively groom cage-mates, as opposed to themselves. While
these modalities may be beneficial in assessing wider
trends, their utility in optimizing treatment based on indi-
vidual traits may be more limited.
We suggest that current diagnostic classification of GD
is arbitrary but pragmatic given available evidence. Classify-
ing GD with OCD in the DSM-5 encourages clinicians to
screen for relevant comorbidities and encourages research
to support or refute this conceptualization. Whether the
International Statistical Classification of Diseases and
Related Health Problems, Eleventh Revision will adopt a
similar classification remains unclear because GDs are cur-
rently listed in a separate category to OCD in the Interna-
tional Statistical Classification of Diseases and Related Health
Problems, Tenth Revision. Despite possible neurobiological
or cognitive distinctions, it may be beneficial to classify GD
and OCD under a common heading based on similar symp-
toms, given that not all clinicians have experience with GD
and may conflate symptoms with OCD unless distinct
guidelines are provided, as is often the case with disorders
falling under a common classification.
Also of relevance here is the concept of behavioral addic-
tion. In an animal model, NAC dampened the effects of co-
caineonglutamate transporters in thenucleusaccumbensand
dorsal striatum.5 Perhaps the beneficial effects of NAC in GD
occurat leastpartlyviaasimilarmechanism,an issuethatcould
be explored further.
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CORRECTION
OmittedStatisticalAnalysisDescriptionandErrors inFigure: In theOriginal In-
vestigation titled “Whole-BodyHyperthermia for theTreatment ofMajorDepres-
sive Disorder: A Randomized Clinical Trial,”1 published online May 12, 2016, there
was an omission in the Methods section and errors in Figure 2. The sentence de-
scribing theCohend calculation in the Statistical Analysis subsectionof theMeth-
ods section should have read as follows: “Cohen dwas calculated to assess effect
sizes for between-group differences at all posttreatment points based onmeans
andSDsderived from themixed-effectmodel.” Therewere also data errors in Fig-
ure 2, which have been corrected, and the accompanying figure caption should
have read as follows: “The error bars indicate SEs. Means and SEs were derived
from the raw data provided in Table 2.” This article was corrected online.
1. Janssen CW, Lowry CA, Mehl MR, et al. Whole-body hyperthermia for the
treatment of major depressive disorder: a randomized clinical trial [published
online May 12, 2016]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2016.1031.
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